Source link : https://www.newshealth.biz/health-news/can-pembrolizumab-improve-dmmr-endometrial-cancer-outcomes/
TOPLINE: Adding pembrolizumab to adjuvant chemotherapy in the first-line setting improved disease-free survival (DFS) in patients with high-risk endometrial cancer who have mismatch repair–deficient (dMMR) tumors, according to a subgroup analysis of a phase 3 study. METHODOLOGY: About 25%-30% of patients with endometrial cancer harbor dMMR tumors, an inflamed phenotype that is associated with poor […]
Author : News Health
Publish date : 2024-10-28 13:12:31
Copyright for syndicated content belongs to the linked Source.
